HK99895A - Hybrid interferons - Google Patents

Hybrid interferons

Info

Publication number
HK99895A
HK99895A HK99895A HK99895A HK99895A HK 99895 A HK99895 A HK 99895A HK 99895 A HK99895 A HK 99895A HK 99895 A HK99895 A HK 99895A HK 99895 A HK99895 A HK 99895A
Authority
HK
Hong Kong
Prior art keywords
interferons
hybrid interferons
novel hybrid
hybrid
interferon
Prior art date
Application number
HK99895A
Other languages
English (en)
Inventor
Meyer Francois Dr
Hinnen Albert Dr
Meister Andreas Dr
Gruetter Markus Gerhard Dr
Alkan Sefik Prof Dr
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858514722A external-priority patent/GB8514722D0/en
Priority claimed from GB858514723A external-priority patent/GB8514723D0/en
Priority claimed from GB858514726A external-priority patent/GB8514726D0/en
Priority claimed from GB858514724A external-priority patent/GB8514724D0/en
Priority claimed from GB858514725A external-priority patent/GB8514725D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of HK99895A publication Critical patent/HK99895A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
HK99895A 1985-06-11 1995-06-22 Hybrid interferons HK99895A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB858514722A GB8514722D0 (en) 1985-06-11 1985-06-11 Hybrid interferon
GB858514723A GB8514723D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
GB858514726A GB8514726D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptides
GB858514724A GB8514724D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
GB858514725A GB8514725D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptide

Publications (1)

Publication Number Publication Date
HK99895A true HK99895A (en) 1995-06-30

Family

ID=27516593

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99895A HK99895A (en) 1985-06-11 1995-06-22 Hybrid interferons

Country Status (20)

Country Link
US (2) US4885166A (no)
EP (1) EP0205404B1 (no)
JP (2) JPH0655759B2 (no)
KR (1) KR920002267B1 (no)
AT (1) ATE78262T1 (no)
AU (1) AU598196B2 (no)
CA (1) CA1285507C (no)
CY (1) CY1842A (no)
DE (1) DE3685996T2 (no)
DK (1) DK168794B1 (no)
FI (1) FI90983C (no)
GR (1) GR861497B (no)
HK (1) HK99895A (no)
HU (1) HU203255B (no)
IE (1) IE57865B1 (no)
IL (1) IL79085A (no)
NO (1) NO175602C (no)
NZ (1) NZ216485A (no)
PT (1) PT82736B (no)
SG (1) SG25195G (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
EP0331635A3 (en) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Preparations for treating bladder cancer
US5273889A (en) * 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
JP3149182B2 (ja) * 1990-08-29 2001-03-26 ジェネティックス・インスティテュート・インコーポレイテッド 多領域造血刺激因子類
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
DE69222013T2 (de) * 1991-12-16 1998-01-29 Ciba Geigy Ag Endoplasmatisches Retikulum-ständige rekombinante dibasische Endoprotease und deren Verwendungen
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
DE69323131T2 (de) * 1992-03-10 1999-09-16 La Jolla Cancer Research Foundation, La Jolla Rekombinierte alkalische phosphatase aus kälberdarm
TW218846B (no) * 1992-04-07 1994-01-11 Ciba Geigy
JPH078215A (ja) * 1993-04-30 1995-01-13 Kawasaki Steel Corp ドコサヘキサエン酸含有海洋性微細藻類食品素材およびその製造方法
TW249202B (no) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
ATE207538T1 (de) 1995-02-09 2001-11-15 Behringwerke Ag Verfahren zur produktion von proteinen
TW442492B (en) * 1995-07-26 2001-06-23 Novartis Ag Process for the enrichment of interferon
US6685933B1 (en) * 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
IL142282A0 (en) 1998-10-16 2002-03-10 Biogen Inc Compositions containing polymer conjugates of interferon-beta-1a
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
AU2002225870B2 (en) * 2000-11-03 2006-09-21 Intarcia Therapeutics, Inc. Method for short-term and long-term drug dosimetry
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
KR20040053291A (ko) * 2001-11-09 2004-06-23 바이오메디신즈 인코포레이티드 오메가 인터페론을 이용한 질환 치료 방법
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
KR20050086498A (ko) * 2002-11-18 2005-08-30 맥시겐, 인크. 인터페론-알파 폴리펩티드 및 접합체
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
AU2005245918A1 (en) 2004-05-19 2005-12-01 F. Hoffmann-La Roche Ag Interferon-alpha polypeptides and conjugates
JP2008509889A (ja) * 2004-06-30 2008-04-03 イージェン コーポレーション ペグ化インターフェロンα−１ｂ
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
BRPI0609809A2 (pt) 2005-05-18 2011-10-11 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado
CN101453982B (zh) 2006-05-30 2011-05-04 精达制药公司 两件式内部通道渗透递送系统流动调节器
SI2041259T1 (sl) 2006-07-14 2016-04-29 Dpx Holdings B.V. Izboljšan postopek kultiviranja celic
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
AU2007327993B2 (en) 2006-12-06 2013-06-20 Medimmune, Llc. Methods of treating systemic lupus erythematosus
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
AU2008247815B2 (en) * 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
AU2008247395A1 (en) 2007-05-03 2008-11-13 Medimmune, Llc Auto-antibody markers of autoimmune disease
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
EP2219452B1 (en) 2007-11-05 2015-10-14 MedImmune, LLC Methods of treating scleroderma
CA2714410A1 (en) 2008-02-08 2009-08-13 Medimmune, Llc Disease markers and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
MX2012002640A (es) 2009-09-03 2012-06-25 Medimmune Llc Diagnostico de interferon tipo 1.
CN104323981B (zh) 2009-09-28 2019-03-12 精达制药公司 基本稳态药物递送的快速建立和/或终止
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2686002B1 (en) 2011-03-15 2018-01-24 Biogen Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
US8729236B2 (en) * 2011-05-23 2014-05-20 Hal S. Padgett Selection and characterization of novel plant-derived recombinant human interferons with broad spectrum activity
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
MX2018014016A (es) 2016-05-16 2019-08-01 Intarcia Therapeutics Inc Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
AU2020222262B2 (en) 2019-02-15 2024-06-20 Astrazeneca Ab Type I interferon-mediated disorders
KR102594862B1 (ko) * 2023-06-14 2023-10-27 (주) 신성하이스킬 화재방지 파쇄 시스템
KR102570958B1 (ko) * 2023-06-14 2023-08-25 (주) 신성하이스킬 화재방지 4축 파쇄장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO164037C (no) * 1980-01-08 1990-08-22 Biogen Inc Fremgangsmaate ved fremstilling av et polypeptid av interferon alfa (ifnalfa)-type.
ES506955A0 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
IT1167610B (it) * 1982-01-19 1987-05-13 Cetus Corp Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
EP0146903A3 (en) * 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
EP0173935A1 (en) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
US4716217A (en) * 1984-08-31 1987-12-29 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons

Also Published As

Publication number Publication date
EP0205404A3 (en) 1987-10-21
NO862313D0 (no) 1986-06-10
PT82736B (pt) 1988-12-15
PT82736A (en) 1986-07-01
IE861542L (en) 1986-12-11
DK168794B1 (da) 1994-06-13
FI90983C (fi) 1994-04-25
DK272986A (da) 1986-12-12
IE57865B1 (en) 1993-05-05
FI862461A (fi) 1986-12-12
US4885166A (en) 1989-12-05
DE3685996D1 (de) 1992-08-20
GR861497B (en) 1986-10-10
US5071761A (en) 1991-12-10
HU203255B (en) 1991-06-28
NO175602C (no) 1994-11-02
IL79085A0 (en) 1986-09-30
DK272986D0 (da) 1986-06-10
KR920002267B1 (ko) 1992-03-20
IL79085A (en) 1992-03-29
AU598196B2 (en) 1990-06-21
CA1285507C (en) 1991-07-02
JPH05308973A (ja) 1993-11-22
KR870000427A (ko) 1987-02-18
FI862461A0 (fi) 1986-06-09
EP0205404B1 (en) 1992-07-15
DE3685996T2 (de) 1993-01-14
NZ216485A (en) 1991-06-25
CY1842A (en) 1996-03-08
JPH0655759B2 (ja) 1994-07-27
JPH0736757B2 (ja) 1995-04-26
FI90983B (fi) 1994-01-14
EP0205404A2 (en) 1986-12-17
NO175602B (no) 1994-07-25
AU5849986A (en) 1986-12-18
ATE78262T1 (de) 1992-08-15
SG25195G (en) 1995-08-18
HUT41846A (en) 1987-05-28
NO862313L (no) 1986-12-12
JPS626000A (ja) 1987-01-12

Similar Documents

Publication Publication Date Title
SG25195G (en) Hybrid interferons
DE3583521D1 (de) Antivirale verbindungen.
AU2964489A (en) Dna sequences, recombinant dna molecules and processes for producing human immune interferon-like polypeptides
ES8500996A1 (es) Meotod de producir un polipeptido.
EP0263072A3 (en) Novel lymphokine related peptides
GB2121474B (en) Two-stage i.c. engine turbocharging
IE851906L (en) Interferons
NZ228105A (en) Antihypertensive hyperimmune milk, its production and medicaments therefrom
EP0315637A4 (en) POLYPEPTIDES USEFUL IN THE DIAGNOSIS OF MYCOPLASMA INFECTIONS IN PIGS, AND RECOMBINANT DNA METHODS FOR THEIR MANUFACTURE.
AU598460B2 (en) Process preparing and purifying interferon
ES8404373A1 (es) Un procedimiento para obtener compuestos de ribofuranosilselenazol-4-carboxamida.
EP0191854A4 (en) ANTIVIRAL PEPTIDES.
AU4970885A (en) Novel lymphokine, monoclonal antibody specific to the lymphokine, and their production and uses
ES2001108A6 (es) Un procedimiento para la preparacion de un derivado de gem-dihalo-1,8-diamino -4 -aza-octano.
EP0276120A3 (en) Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
ZA877417B (en) Novel lymphokine related peptides
SU939352A1 (ru) Двухмассный вибрационный конвейер
SG134394G (en) Genetic sequences, type I interferon peptide coded by them, and these organisms producing the same

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20060604